Paramita Ghosh, M.Sc., Ph.D.

Paramita M. Ghosh, M.Sc., Ph.D.


  • Professor


Oak Park Research Center Building

2700 Stockton Blvd. Room 1132
Sacramento, CA 95817
Driving Directions

Primary Phone:

Additional Phone Numbers

Clinic Fax: 916-734-8904
Clinic Referral Phone: 916-734-7805
Physician Referrals: 800-4-UCDAVIS (800-482-3284)

Research/Academic Interests

My current research concentrates on the study of signal transduction pathways involved in prostate cancer development and progression. This includes studies on the EGFR family of receptor tyrosine kinases, leading to the PI3K/Akt pathway and finally to the mTOR signaling pathway. In particular, I investigate the interaction of these pathways with the androgen receptor.

My research involves identification of significant therapeutic targets, as well as studying the effects of inhibitors of those targets both in vitro as well as in animal models. I am currently funded to study drug combinations that target parallel signaling pathways and in combination, appear to be highly effective in inhibiting the progression of prostate cancer.



Center/Program Affiliation

UC Davis Comprehensive Cancer Center


B.Sc., Jadavpur University, Calcutta, India 1986

M.Sc., Jadavpur University, Calcutta, India 1988

Ph.D., Rensselaer Polytechnic Institute, Troy NY 1994

B.Sc., Jadavpur University, Calcutta, India 1986

Ph.D., Renesselaer Polytechnic Institute, Troy NY 1994


Pathology, University of Texas Health Science Center, San Antonio TX 1994-2000

Professional Memberships

American Association for Cancer Research

American Association for the Advancement of Science

American Urological Association

The Society for Basic Urologic Research

Select Recent Publications

Shih TC, Liu R, Wu CT, Li X, Xiao W, Deng X, Kiss Z, Wang T, Chen X, Carney RP, Kung HJ, Duan Y, Ghosh PM, Lam KS. Targeting Galectin-1 impairs castration-resistant prostate cancer progression and invasion. Clin Cancer Res. 24(17):4319-4331. 2018.

D'Abronzo LS, Ghosh PM. eIF4E Phosphorylation in Prostate Cancer. Neoplasia. 20(6):563-573.

D'Abronzo LS, Pan CX, Ghosh PM. Evaluation of Protein Levels of the Receptor Tyrosine Kinase ErbB3 in Serum. Methods Mol Biol. 1655:319-334. 2018.

Kent MS, Zwingenberger A, Westropp JL, Barrett LE, Durbin-Johnson BP, Ghosh P, Vinall RL. MicroRNA profiling of dogs with transitional cell carcinoma of the bladder using blood and urine samples. BMC Vet Res. 13(1):339. 2017.

D'Abronzo LS, Bose S, Crapuchettes ME, Beggs RE, Vinall RL, Tepper CG, Siddiqui S, Mudryj M, Melgoza FU, Durbin-Johnson BP, deVere White RW, Ghosh PM. The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer. Oncogene. 36(46):6359-6373. 2017.

Shih TC, Liu R, Fung G, Bhardwaj G, Ghosh PM, Lam KS. A Novel Galectin-1 Inhibitor Discovered through One-Bead Two-Compound Library Potentiates the Antitumor Effects of Paclitaxel in vivo. Molecular cancer therapeutics. 16(7):1212-1223. 2017.

Kiss Z, Ghosh PM. Circadian rhythmicity and the influence of 'clock' genes on prostate cancer. Endocrine-related cancer. 2016 Nov;23(11):T123-T134.

Chow H, Ghosh PM, deVere White RW, Evans CP, Dall’Era MA, Yap SA, Li Y, Beckett LA, Lara PN, Pan CX. A Phase II clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer. Cancer. 2016 Jun 15;122(12):1897-904.

Pan, CX, Zhang, H, Tepper, CG, Lin, TY, Davis, RR, Keck, J, Ghosh, PM, Gill, P, Airhart, S, Bult, C, Gandara, DR, Liu, E, de Vere White, RW. Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy. PloS one. 2016;10(8): e0134346.

Savoy, R.M., Chen, L., Siddiqui, S., Melgoza, F.U., Durbin-Johnson, B., Drake, C., Jathal, M.K., Bose, S., Steele, T.M., Mooso, B.A., D’Abronzo, L.S., Fry, W.H., Carraway, K.L. III, Mudryj, M. and Ghosh, P.M. Transcription of Nrdp1 by the androgen receptor is regulated by nuclear Filamin A in prostate cancer. Endocrine-related Cancer. 2015. Mar 10. pii: ERC-15-0021 (PMID: 25759396).